Vedolizumab response in inflammatory bowel disease. Two years of follow-up.
Pilar Del Pino BellidoMaría Belvis JiménezLuisa Castro LariaMaría Belén Maldonado PérezAntonia Sáez DíazÁngel Caunedo ÁlvarezFederico Argüelles-AriasPublished in: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva (2021)
vedolizumab is effective for induction and maintenance of clinical remission, both in Crohn's disease and ulcerative colitis.
Keyphrases